GZYJPCO(SH:603058) Sou Hu Cai Jing·2026-02-02 23:14Overview of External Investment - Guizhou Yongji Printing Co., Ltd. approved an external investment agreement on January 26, 2025, to acquire 100% equity of Phytoca Holdings through its wholly-owned subsidiary Yongji Health Pty Ltd, with an investment amount of approximately AUD 62.2951 million (about RMB 282 million) [3][4]. Progress of External Investment - The first phase of equity transfer was completed on April 7, 2025, with Yongji Health holding 60% of Phytoca Holdings, which will be included in the company's consolidated financial statements [5][6]. Second Phase Equity Purchase Price Determination - The purchase price for the second phase is not fixed but will be dynamically adjusted based on Phytoca Holdings' audited EBIT for the fiscal year 2025 [7][8]. - The audited EBIT for Phytoca Holdings for the fiscal year 2025 was AUD 8,481,083.16 (approximately RMB 41 million) [9][11]. Calculation of Second Phase Purchase Price - The final purchase price for the second phase was determined to be AUD 38,509,532.35 (approximately RMB 187 million), which is higher than the expected purchase price of AUD 20,781,482.40 (approximately RMB 101 million) [10][11]. - The increase in the purchase price was due to the actual audited EBIT exceeding initial expectations by AUD 246,220 [11]. Subsequent Arrangements - The funding for the second phase equity acquisition will consider self-funding, self-raised funds, and other financing channels. The company plans to apply for a merger loan of RMB 100 million to support the acquisition [12][13]. Impact of External Investment and Merger Loan - The acquisition is a crucial part of the company's external investment strategy, enhancing its presence in the regulated pharmaceutical market in Australia and improving long-term profitability and competitiveness [18]. - The merger loan application is expected to optimize the company's financing structure and support the acquisition without posing significant financial risks [19].